New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 6, 2014
07:20 EDTKPTIKaryopharm price target raised to $50 from $25 at JMP Securities
JMP Securities raised its price target on Karyopharm after it provided an outline of planned pivotal trials in AML, DLBCL, and Richterís syndrome, and formally stated that it is broadening its Phase II development plans in various solid tumor malignancies. The firm sees unmet need in these indications and its confidence in the company's chances of success has increased. It increased its estimate of peak U.S. sales for selinexor to $3.6B from $1.8B and reiterates an Outperform rating.
News For KPTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 16, 2015
07:15 EDTKPTIKaryopharm expects existing cash will fund R&D programs into 2018
Based on current operating plans, Karyopharm expects that its existing cash and cash equivalents will fund its research and development programs and operations into 2018, including moving registration-directed clinical studies to their next data inflection points. Karyopharm expects to end 2015 with greater than $200M in cash, cash equivalents and investments.
07:13 EDTKPTIKaryopharm reports Q4 EPS (79c), consensus (65c)
Reports Q4 revenue $16,000, consensus $40,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use